不同抗抑郁药物对抑郁症患者血清S100B蛋白和BDNF浓度与认知功能的影响
|
摘要
目的探究不同抗抑郁药物对抑郁症患者血清S100B蛋白(S100B)和血清脑源性神经营养因子(BDNF)浓度与认知功能的影响。方法将120例抑郁症患者采用随机数表法分为观察组和对照组,每组60例。观察组予以阿戈美拉汀治疗,对照组予以文拉法辛治疗。比较2组治疗前、治疗6w后症状[汉密尔顿抑郁量表(HAMD)、蒙哥马利抑郁量表(MARDS)],认知功能[重复性成套神经心理状态测验(RBANS)],愉快体验感受[斯奈思-汉密尔顿快感量表(SHAPS)]、血清S100B及BDNF水平的差异,并记录2组不良反应发生率。结果治疗6w后,2组症状严重程度(HAMD、MARDS得分)、SHAPS得分和S100B水平均低于治疗前(P<0.05),2组RBANS得分和BDNF水平均高于治疗前(P<0.05),且观察组变动幅度大于对照组(P<0.05)。结论阿戈美拉汀应用于抑郁症患者效果优于文拉法辛,S100B和BDNF指标水平更优,同时在改善患者疾病症状、认知功能和愉悦体验中作用也更明显。
Objective To explore the effects of different anti-depressant drugs on serum S100 B protein(S100 B)and brain-derived neurotrophic factor(BDNF)and cognitive function in patients with depression. Methods 120 depression patients were divided into observation group(n=60)and control group(n=60)by random number table method. Observation group was given agomelatine,and control group was given venlafaxine. The symptoms(Hamilton Depression Scale(HAMD),Montgomery Depression Scale(MARDS)],cognitive function [Repeatable Battery for the Assessment of Neuropsychological Status(RBANS)],and experience of pleasure [Snaith-Hamilton Pleasure Scale(SHAPS)] and serum S100 B and BDNF levels were compared between two groups before treatment and after 6 weeks of treatment,and the incidence rate of adverse reactions was recorded in two groups. Results After 6 weeks of treatment,symptoms severity(HAMD,MARDS scores),SHAPS score and S100 B level in two groups were lower than those before treatment(P<0.05)while RBANS score and BDNF level were higher than those before treatment(P<0.05),and changes degree in observation group was greater than that in control group(P<0.05). Conclusions Agomelatine is more effective than venlafaxine in depressive patients,and S100 B and BDNF levels are better in former one,and it has significant roles in improving patient's symptoms,cognitive function and pleasure experience.
Objective To explore the effects of different anti-depressant drugs on serum S100 B protein(S100 B)and brain-derived neurotrophic factor(BDNF)and cognitive function in patients with depression. Methods 120 depression patients were divided into observation group(n=60)and control group(n=60)by random number table method. Observation group was given agomelatine,and control group was given venlafaxine. The symptoms(Hamilton Depression Scale(HAMD),Montgomery Depression Scale(MARDS)],cognitive function [Repeatable Battery for the Assessment of Neuropsychological Status(RBANS)],and experience of pleasure [Snaith-Hamilton Pleasure Scale(SHAPS)] and serum S100 B and BDNF levels were compared between two groups before treatment and after 6 weeks of treatment,and the incidence rate of adverse reactions was recorded in two groups. Results After 6 weeks of treatment,symptoms severity(HAMD,MARDS scores),SHAPS score and S100 B level in two groups were lower than those before treatment(P<0.05)while RBANS score and BDNF level were higher than those before treatment(P<0.05),and changes degree in observation group was greater than that in control group(P<0.05). Conclusions Agomelatine is more effective than venlafaxine in depressive patients,and S100 B and BDNF levels are better in former one,and it has significant roles in improving patient's symptoms,cognitive function and pleasure experience.
引文
1.Yang H,Xiang H,Qin Q.A randomized controlled trial of right low frequency rTMS combined with escitalopram in treatment of first-episode with depression in general hospital[J].Journal of International Psychiatry,2017,2(5):1-6.
2.罗新,崔凤伟,陆伟琦.文拉法辛缓释胶囊与舍曲林治疗抑郁症的临床疗效和安全性对照研究[J].山西医药杂志,2015,44(12):1392-1394.
3.孙磊,陈清刚,王莹,等.阿戈美拉汀与帕罗西汀对首发抑郁症患者认知功能的影响[J].中国药房,2016,27(11):1545-1547.
4.王飞,姚欣耀,聂杰.丙泊酚静脉麻醉对前列腺电切术后患者血清BDNF、S100B蛋白及认知功能的影响[J].实用药物与临床,2016,19(2):183-186.
5.Anonymous.The International Classification of Diseases,10th Edition(ICD-10)changeover is coming[J].Optometry-journal of the American Optometric Association,2010,81(10):551.
6.欧秋明,邓思灵.米氮平联合草酸艾司西酞普兰片治疗抑郁症的临床疗效及安全性评价[J].中国临床药理学杂志,2015,31(13):1252-1254.
7.刘浩,张鸿燕,肖卫东,等.5种抑郁症状评定工具评估精神分裂症患者抑郁症状的比较[J].中国心理卫生杂志,2015,29(8):570-575.
8.张保华,谭云龙,张五芳,等.重复性成套神经心理状态测验的信度、效度分析[J].中国心理卫生杂志,2008,22(12):865-869.
9.胡旭强,钱敏才,林敏,等.斯奈思-汉密尔顿快感量表中文版测评抑郁症患者的效度和信度[J].中国心理卫生杂志,2017,31(8):625-629.
10.沈仲夏,钱敏才,蔡敏,等.阿戈美拉汀治疗抑郁症及其对患者性功能的影响[J].中国临床药理学与治疗学,2016,21(7):806-810.
11.王彦芳,杜巧荣,李素萍,等.伴发睡眠障碍首发抑郁症认知功能损害及影响因素分析[J].中国神经精神疾病杂志,2015,41(02):71-75.
12.甄莉丽,蒋幸衍,赵幸福,等.首发抑郁障碍患者血清S100B蛋白水平的Meta分析[J].中国现代医学杂志,2015,25(14):67-72.
13.郭青山,刘忠纯,姚丽华,等.抑郁症患者治疗前后血清白介素-6及脑源性神经营养因子水平的变化及其相应的临床意义[J].国际精神病学杂志,2015,42(02):15-18.
2.罗新,崔凤伟,陆伟琦.文拉法辛缓释胶囊与舍曲林治疗抑郁症的临床疗效和安全性对照研究[J].山西医药杂志,2015,44(12):1392-1394.
3.孙磊,陈清刚,王莹,等.阿戈美拉汀与帕罗西汀对首发抑郁症患者认知功能的影响[J].中国药房,2016,27(11):1545-1547.
4.王飞,姚欣耀,聂杰.丙泊酚静脉麻醉对前列腺电切术后患者血清BDNF、S100B蛋白及认知功能的影响[J].实用药物与临床,2016,19(2):183-186.
5.Anonymous.The International Classification of Diseases,10th Edition(ICD-10)changeover is coming[J].Optometry-journal of the American Optometric Association,2010,81(10):551.
6.欧秋明,邓思灵.米氮平联合草酸艾司西酞普兰片治疗抑郁症的临床疗效及安全性评价[J].中国临床药理学杂志,2015,31(13):1252-1254.
7.刘浩,张鸿燕,肖卫东,等.5种抑郁症状评定工具评估精神分裂症患者抑郁症状的比较[J].中国心理卫生杂志,2015,29(8):570-575.
8.张保华,谭云龙,张五芳,等.重复性成套神经心理状态测验的信度、效度分析[J].中国心理卫生杂志,2008,22(12):865-869.
9.胡旭强,钱敏才,林敏,等.斯奈思-汉密尔顿快感量表中文版测评抑郁症患者的效度和信度[J].中国心理卫生杂志,2017,31(8):625-629.
10.沈仲夏,钱敏才,蔡敏,等.阿戈美拉汀治疗抑郁症及其对患者性功能的影响[J].中国临床药理学与治疗学,2016,21(7):806-810.
11.王彦芳,杜巧荣,李素萍,等.伴发睡眠障碍首发抑郁症认知功能损害及影响因素分析[J].中国神经精神疾病杂志,2015,41(02):71-75.
12.甄莉丽,蒋幸衍,赵幸福,等.首发抑郁障碍患者血清S100B蛋白水平的Meta分析[J].中国现代医学杂志,2015,25(14):67-72.
13.郭青山,刘忠纯,姚丽华,等.抑郁症患者治疗前后血清白介素-6及脑源性神经营养因子水平的变化及其相应的临床意义[J].国际精神病学杂志,2015,42(02):15-18.